Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Cerus CorporationNASDAQ: CERS

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns positive

Q1 FY2026 investing cash flow was $9.86M, compared with -$1.19M a year earlier. Trailing-twelve-month investing cash flow was $4.88M.

Context

  • Investing cash flow amounted to 3.9% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near $9.86M or moves back toward the trailing-twelve-month quarterly average of $1.22M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.86M+815.5% QoQ
Last fiscal yearDec 2025
-$8.13M+0.0% YoY
LTMMar 2026
$4.88M+145.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+929.3%——
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(8.13M) USD
Year-over-year change
+0.0%

Investing Cash Flow vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +145.4% is the 2nd highest of 4, against a peer median of +30.7%.
  • Investing cash flow amounts to 2.2% of revenue for CERS, versus a peer median of 7.0%.
CERS Competitors
Investing Cash Flow for CERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€521.95M EUR-23.2%-34.5%7.0%
HAEHaemonetics CorporationLTM Jun 2026$168.78M USD+203.0%+7.7%12.5%
ADMAADMA Biologics, Inc.LTM Jun 2026$14.5M USD+30.7%+16.3%2.8%
CERSCerus CorporationLTM Mar 2026$4.88M USD+145.4%—2.2%
Peer median (excluding CERS) —+30.7%+7.7%7.0%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.38M)(42.83M)(37.49M)(20.96M)(15.63M)
Depreciation & Amortization3.15M2.98M2.6M1.86M1.86M
Deferred Income Tax462K0000
Stock-Based Compensation23.57M24.46M20.27M22.87M22.87M
Change in Working Capital(9.4M)(16.05M)(32.04M)5.23M(6.83M)
Accounts Receivables(4.22M)(9.2M)(1.1M)5.5M(396K)
Inventory(19.61M)(1.77M)(14.95M)7.03M(14.68M)
Accounts Payables12.2M(4.91M)(7.34M)(1.48M)5.73M
Other Working Capital2.22M(179K)(8.65M)(5.83M)2.52M
Other Non-Cash Items2.67M5.82M3.49M2.37M9.09M
Operating Cash Flow(33.92M)(25.62M)(43.17M)11.36M11.36M
Capital Expenditures(910K)(2M)(4.6M)(2.84M)(2.84M)
Acquisitions (Net)910K(10.46M)000
Purchases of Investments(52.07M)(29.64M)(2.49M)(42.98M)(42.98M)
Sales of Investments65.66M40.1M15.71M37.68M37.68M
Other Investing Activities(910K)10.46M000
Investing Cash Flow12.69M8.46M8.62M(8.13M)(8.13M)
Debt Repayment21.18M212K9.92M4.3M(329K)
Common Stock Issued2.74M000560K
Common Stock Repurchased0(104K)(175K)00
Dividends Paid00000
Other Financing Activities10.37M4.08M925K667K4.73M
Financing Cash Flow34.29M4.19M10.67M4.96M4.96M
Effect of Forex Changes(919K)(727K)(128K)(191K)(191K)
Net Change in Cash12.14M(13.69M)(24M)8M8M
Free Cash Flow(34.83M)(27.62M)(47.77M)8.52M8.52M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.